Postgraduate Institute for Medicine, in Partnership with RMEI Medical Education, Announces an Educational Awareness Campaign for World Arthritis Day
Postgraduate Institute for Medicine (PIM) and RMEI Medical Education (RMEI) have launched the first in a three-part series of global medical education interventions to address ongoing gaps in clinical practice, and to raise awareness for World Arthritis Day by focusing on the importance of early diagnosis and access to evidence-based treatment in rheumatoid arthritis (RA). The partners hope the first activity will stimulate professional reflection on practice behavior and patient outcomes, while later content will address emerging data on therapeutic pathways and patient engagement.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171012005711/en/
The series is entitled Achieving Success in RA Assessment and Management: A Learner Pathway to Improve Patient Outcomes, and will incorporate alternating cycles of education, assessment, and recalibration of content to meet evolving healthcare provider needs.
“If pharmacological treatment for rheumatoid arthritis is started within 12 weeks after the onset of symptoms, this could minimize the level of joint impact over time and increase the chances of remission1,” noted Dr. Jeffrey Curtis, professor of medicine and director of the Arthritis Clinical Intervention Program at the University of Alabama at Birmingham, in the United States. “Both EULAR and ACR guidelines advocate for a treat-to-target approach with shared decision making. There has been a general failure to adopt this in clinical practice, and the weight of the evidence is that these approaches work to optimize care for patients with RA.”
Each of the 3 online courses will present learners with unique educational environments: the first, called Clinical Reflections™, uses a virtual clinical setting to allow learners to rethink decisions based on realistic patient care scenarios and to modify their management plans accordingly to affect behavioral change. The second, Clinical Convergence ®, engages learners by integrating video patient perspectives with clinical content to illustrate potential differences between clinician and patient perceptions of their care. The third and final course, Clinical Conversations™, teaches clinicians certain technical skills and a step-wise process for integrating shared decision-making into patient care, a core competency not taught extensively in medical school and not appropriately utilized by clinicians in various specialties and disciplines.
Supported by independent educational grant funding from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals, this advanced analytics-driven initiative is the first of its kind in the RA education field.
“Why this is important to patients with RA might seem obvious, since clinicians who engage in RA-related education tailored to specific drivers of educational need tend to improve the care they deliver to their patients,” said Jacqui Brooks, MBBCh, MRCPsych, Senior Vice President of Medical Strategy at RMEI. “Our research has shown that proactive monitoring of disease activity and selecting appropriate treatment options – particularly in patients with moderate to severe disease – as well as use of shared decision-making approaches, are areas of particular deficit. The Learner Pathway in RA will address these issues with laser-like focus.”
This initiative has been planned to support EULAR’s “Don’t Delay, Connect Today” campaign, an initiative for uniting the voices of People with Arthritis and Rheumatism (PARE) organizations, scientific member societies, and health professional associations, with the united goal of highlighting the importance of early diagnosis and access to treatment.
About RMEI Medical Education
Founded in 1990, RMEI Medical Education (RMEI) is one of the longest operating medical education companies in the US. With an emphasis on sophisticated learner analytics for program design, delivery, and assessment, RMEI works to elevate the dialogue on what makes for effective education. In designing innovative teaching modalities such as the Clinical Convergence™ platform for its 5 primary therapeutic areas, RMEI seeks to inspire greater collaboration within the care team and stronger commitment to patient engagement. For more information, visit www.rmei.com, call 856-672-3152, or e-mail at email@example.com.
The European League Against Rheumatism (EULAR) is a pan-European, non-profit organization that represents people with arthritis/rheumatism, health professionals in rheumatology, and scientific societies of rheumatology across Europe. EULAR aims to reduce the burden of rheumatic and musculoskeletal diseases (RMDs) on the individual and society and to improve the treatment, prevention, and rehabilitation of them. It promotes the translation of research advances into improved daily care for people with RMDs, and fights for governing bodies in Europe to recognize the needs of people with RMDs.
EULAR’s members include scientific societies, health professional associations, patient organizations, corporate members and people with RMDs across Europe. 2017 marks the 70th anniversary of EULAR, marking 70 years of research and the collaboration between physicians, health professionals, and patients. For more information, please visit www.eular.org.
1 Van der Linden MP, le Cessie S, Raza K, et al. Long-Term Impact of Delay in Assessment of Patients with Early Arthritis. Arthritis Rheum. 2010;62(12):3537-3546.
RMEI Medical Education
Dave Clausen, CHCP, 856-672-3152
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis21.2.2018 21:01 | Pressemelding
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation. The study will enroll 360 patients, and the primary endpoint of the study is the mean absolute change from baseline in percent predicted forced expiratory volume in one second (ppFEV1) at week four of treatment. The study is designed to support the submission of a New Drug Application (NDA) in the U.S. using data from the 4-week primary efficacy endpoint together with safety data through 12 weeks of treatment. “Our goal is to bring the best triple combination to patients as rapidly as possible, and this first Phase 3 study of VX-659 in combination with tezacaftor and ivacaftor is a significant step toward that goal,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical
Universal Laser Systems® Expands Portfolio of Laser Material Processing Systems with the ULTRA Platform Series21.2.2018 18:00 | Pressemelding
ULTRA platform-based laser systems are designed and ideally suited for precision laser cutting, laser ablation, and laser surface modification in manufacturing, research and development, academic research and prototyping environments. Major features of the series include rapid, high-accuracy laser beam positioning, and the flexibility to be configured with 9.3 and 10.6 µm CO2 lasers and 1.06 µm fiber lasers. All lasers are air-cooled in a range of power from 10 to 150 watts for CO2 and 40 to 50 watts for fiber lasers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005364/en/ The ULTRA 9MW offers MultiWave processing of thin materials. (Photo: Business Wire) The variety of wavelengths and power ranges make the ULTRA platforms highly effective in the areas of organic material modification, including plastic films, industrial fabrics, engineering plastics, laminating adhesives, composite materials, and many others utilized
Luxoft One of Six Companies Collaborating with Amazon Web Services to Accelerate Blockchain Adoption21.2.2018 16:30 | Pressemelding
Luxoft Holding Inc (NYSE:LXFT), a global IT service provider, announces today that it is collaborating with Amazon Web Services (AWS) to enable corporates to adopt blockchain and Distributed Ledger Technologies (DLT). Luxoft is one of six IT and consulting services companies to make its blockchain advisory and development services available to AWS users. “We are very excited to be working with AWS to help users engage with blockchain and DLTs,” said Vasiliy Suvorov, Vice President of Technology Strategy at Luxoft. “Blockchain is about removing data silos, improving trust and operational efficiencies. By using AWS to deploy and integrate DLTs into day-to-day processes, businesses can revolutionize how they operate.” Luxoft helps accelerate the deployment and integration of blockchain and DLT-based projects on AWS and is already working on a number of DLT projects using the cloud. For example, Luxoft is building a healthcare claims processing system for a leading healthcare provider usin
Westinghouse Electric Company to Provide Engineering Support at Vandellós 1 in Partnership with EDF21.2.2018 16:30 | Pressemelding
Westinghouse Electric Company and Electricité de France (EDF), in partnership, announced today that they have been awarded a contract from Empresa Nacional de Residuos Radiactivos (ENRESA), the Spanish agency responsible for radioactive waste management and nuclear plant decommissioning. The agreement covers a four-year engineering support contract for the latency phase of the dismantling and decommissioning project at Vandellós I Nuclear Power Station in Spain and includes the preparation of technical and licensing documentation. “We are extremely pleased that ENRESA has selected Westinghouse and EDF to continue supporting the decommissioning activities at Vandellós I Nuclear Power Station,” said Yves Brachet, Westinghouse vice president, Global Decommissioning, Decontamination, Remediation and Waste Management. “This contract further demonstrates Westinghouse’s global capabilities and expertise in providing innovative decommissioning solutions.” Sylvain Granger, head of EDF's decommi
H.I.G. Europe Completes a Strategic Investment in Puerto de Indias Group21.2.2018 14:02 | Pressemelding
H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €20 billion of equity capital under management, announced that one of its affiliates has acquired a majority interest in Puerto de Indias Group (“Puerto de Indias” or the “Company”), with the goal of accelerating the Company’s growth initiatives and supporting its expansion into international markets. Headquartered in Seville, Spain, Puerto de Indias was founded by Jose Antonio and Francisco Rodriguez Fernandez, and has become in a short period of time the leading player in the Rosé Gin market in Spain. Puerto de Indias has in place an ambitious international expansion plan targeting the development of a commercial network in Europe, the U.S., and Latin America, as well as strategic alliances with strong international distributors. Leopoldo Reaño, Principal at H.I.G. Europe, commented on the transaction: “We are thrilled to have the opportunity to support the management team led by Jose Antonio an
Savi Adds Supply Chain Star Johannes Giloth to Advisory Board21.2.2018 13:02 | Pressemelding
Savi®, an innovator in big data/machine learning analytic solutions, supply chain management software, and sensor technology, today announced that Johannes Giloth has joined its board of advisers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005117/en/ Johannes Giloth (Photo: Business Wire) Giloth is a long-time leader in procurement, supply chain and manufacturing. He currently serves as Chief Procurement Officer and Senior Vice President of Operations at Nokia where he is in charge of every aspect of operations accountability worldwide — from demand planning to execution, procurement to manufacturing. “Johannes understands the impact the explosion of data will have on the supply chain. And his tremendous success as an innovative supply chain leader proves he knows what companies need to transform their supply chains,” said Rich Carlson, CEO of Savi Technology. “I’m thrilled to have him join Savi’s advisory board. As